Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.61 |
| ▸ | PRKACA | P17612 | 2/20 | 0.61 |
| ▸ | PRKX | P51817 | 2/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | GSK3A | P49840 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14021151 | 0.94 | PIK3CG (0.59) | PIK3CGPIK3CAPIK3CBROCK1ROCK2 | |
| SCHEMBL14020996 | 0.88 | ROCK2 (0.51) | PIK3CGPIK3CAPIK3CBROCK1ROCK2 | |
| SCHEMBL4377642 | 0.86 | JAK2 (0.61) | PIK3CGPIK3CAPIK3CBROCK1ROCK2 | |
| SCHEMBL14021184 | 0.86 | PIK3CA (0.70) | PIK3CGPIK3CAPIK3CBCYP3A4CYP2C9 | |
| SCHEMBL4919836 | 0.84 | AKT3 (0.52) | PIK3CGPIK3CAPIK3CBROCK1ROCK2 | |
| SCHEMBL3810618 | 0.84 | ROCK2 (0.75) | ROCK1ROCK2PRKACAPRKXPRKCQ | |
| SCHEMBL14021200 | 0.82 | CAMK2D (0.60) | PIK3CGPIK3CAPIK3CBGSK3BABL1 | |
| SCHEMBL4381837 | 0.81 | JAK2 (0.62) | PIK3CGPIK3CAPIK3CBROCK1KDM1A | |
| SCHEMBL14021187 | 0.81 | CAMK2D (0.52) | PIK3CGPIK3CAPIK3CBABL1BCR | |
| SCHEMBL14348407 | 0.81 | CAMK2D (0.72) | PIK3CGROCK1ROCK2PRKACAPRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | claimed |
| EP-1713775-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275062-A1 | Chemical Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | PIK3CG 2493/4885PIK3CA 2475/4885PIK3CB 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.